AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus - Wikidata - wikimedia - TriplyDB

AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus

AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus

http://www.wikidata.org/entity/Q34083071

about

Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.

P2860

Q39039468-0FAB1AF5-19D7-48F5-AF46-C41D0C622C72

P2860

AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus

http://www.wikidata.org/entity/Q34083071

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus

@ast

AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus

@en

AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus

@nl

type

label

AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus

@ast

AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus

@en

AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus

@nl

prefLabel

AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus

@ast

AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus

@en

AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus

@nl

P1433

Q34083071-44552135-8867-4A5E-8761-4E49F2041518

P1476

Q34083071-189492D0-BC87-4E05-949C-3D6116801728

P2093

Q34083071-10D0062A-058B-4C9D-A962-B9E0B5EAA9AA

Q34083071-2EEFE02B-EAC1-462D-846B-61E719E51A12

P2860

Q34083071-0B77A0ED-2E2C-4DBC-BA7D-461CB821BD66

Q34083071-0F9CF814-1D26-4BBE-AAF5-CC1B7C71DA52

Q34083071-102BE048-3A6E-45AE-A976-53FB1DF0587E

Q34083071-11A8A1FF-E47E-47B8-A6B8-6F138DBB8D6F

Q34083071-11E30CC7-9645-4AE3-BCDE-4A5F24D32181

Q34083071-1ED6A5D3-5426-4694-9D36-001268023CA7

Q34083071-2195531C-253A-4DB3-8CB0-6EA60FF3E60C

Q34083071-2908C6E4-79C9-455B-A3AD-128BF273E324

Q34083071-2D42D458-2A46-4AED-9CD6-4DB47E881692

Q34083071-2E6DFCD2-9608-426F-8CE4-AF1CB44E12A0

P2888

Q34083071-303EC078-3AC5-4C44-87A1-A4FF69B9F883

P304

Q34083071-A19ABC05-9234-4E30-86E5-9BE74A430B57

P31

Q34083071-B9585E33-3CDD-4F09-AD1D-23E145C06ACB

P356

Q34083071-C5AF97B0-5C0F-4B1C-8D0F-19F0E771E26C

P478

Q34083071-29D2D8AD-EBAC-4007-ADFE-E96D45741AB1

P577

Q34083071-92FE7FEE-7BFE-4A7D-A798-C48A2C4E75B3

P5875

Q34083071-E5BC1342-BF35-4657-AA9A-0B84DE50FA38

P6179

Q34083071-085856C5-B9E8-482E-8793-14819B09CE48

P698

Q34083071-C0F95058-1C71-496F-9199-CACA95EEB29D

P932

Q34083071-02E39A14-FE89-42D1-919E-A5F9A340DC60

P356

1756-0500-4-511

P1433

BMC Research Notes

P1476

AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus

@en

P2093

Gibson S Kibiki

http://www.w3.org/2001/XMLSchema#string

Hadija H Semvua

http://www.w3.org/2001/XMLSchema#string

P2860

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.

Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection.

Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.

Tolerance of efavirenz in children.

Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.

Tenofovir disoproxil fumarate.

P2888

1756-0500-4-511

P304

511

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1756-0500-4-511

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51828315

http://www.w3.org/2001/XMLSchema#string

P6179

1025228907

http://www.w3.org/2001/XMLSchema#string

P698

22114934

http://www.w3.org/2001/XMLSchema#string

P932

3236078

http://www.w3.org/2001/XMLSchema#string